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a  b  s  t  r  a  c  t
To  investigate  the  venoconstrictor  effect  of  angiotensin  II (Ang  II)  in spontaneously  hypertensive  rats
(SHR),  we used  preparations  of mesenteric  venular  beds  and  the  circular  muscle  of  the  portal  veins.
Vessels  were  tested  with  Ang  II in  the presence  or absence  of  losartan,  PD  123319,  HOE 140,  L-NAME,
indomethacin,  or  celecoxib.  In  the  mesenteric  venular  bed of  SHR,  the  effect  of Ang II (0.1  nmol)  was
nearly  abolished  by  losartan  and  enhanced  by HOE  140, indomethacin,  and celecoxib,  while  PD123319
and  L-NAME  had  no  effect.  In  portal  vein  preparations,  cumulative-concentration  response  curves  (CCRC)
to  Ang  II  (0.1–100  nmol/L)  exhibited  a  lower  maximal  response  (Emax) in  SHR  compared  to  Wistar  rats.  AT1
receptor  expression  was  similar  in  the  two strains,  while  AT2 receptor  levels  were  lower  in SHR  portal
veins  when  compared  to  Wistar.  In  SHR  portal  veins,  losartan  shifted  the  CCRC  to  Ang  II to the right,ngiotensin receptors while  indomethacin  and HOE  140  increased  the  Emax to Ang  II. PD  123319,  celecoxib,  and L-NAME  had
no  effect.  Taken  together,  our  results  suggest  that  Ang  II-induced  venoconstriction  in SHR is  mediated
by  activation  of  AT1 receptors  and  this  effect  may  be counterbalanced  by  kinin  B2 receptor  and  COX
metabolites.  Furthermore,  our data  indicate  that  there are  different  cellular  and  molecular  mechanisms
involved  in  the regulation  of venous  tonus  of  normotensive  and  hypertensive  rats.  These  differences
probably  reﬂect  distinct  factors  that  inﬂuence  arterial  and  venous  bed  in  hypertension.. Introduction
The venous system plays an important role in cardiovascular
omeostasis since it contains about 65% of the total blood vol-
me [25]. The capacitance properties of the cardiovascular system
re primarily determined by veins and venules [24]. Alterations in
enous tonus induced by hormones, peptides or drugs inﬂuence
irectly the cardiac output, right atrial pressure, and, therefore,
ardiac performance [32,37].
Increase  in venous tonus and reduction in venous compliance
ave been described in various models of experimental hyper-
ension [10,16,27,30]; however, data are not conclusive and some
spects remain to be elucidated. Moreover, methodological prob-
ems involved in isolation of veins and venules commit study of
his vascular bed. In spite of this, isolated portal vein and perfused
esenteric venular bed preparations have been used in biologi-
al research to asses venous function in view of the fact that these
reparations respond to a variety of vasoactive agents [32,37]. Since
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splanchnic venous bed accommodates about 25% of the total blood
volume [32] and mesenteric vascular bed can be destination for
10% of cardiac output [37], investigation of venous responses at
these vascular regions could yield important information about
circulatory function and control of blood pressure.
The renin-angiotensin system (RAS) is a coordinated hormonal
cascade important to the regulation of renal sodium excretion and
blood pressure. Angiotensin II (Ang II), the main effector peptide
of RAS, binds two major receptors, AT1 and AT2 (AT1R and AT2R)
[38]. The vast majority of Ang II actions occur via the AT1R binding,
including vasoconstriction, cellular proliferation, and activation of
the sympathetic nervous system [35]. The actions of Ang II medi-
ated by AT2R are less well understood; however, it is known that
AT2R stimulation includes vasodilation, inhibition of cell prolifera-
tion and modulation of growth and remodeling in fetal vasculature
[3].
Ang II promotes vasoconstriction in isolated mesenteric venules
[8,37] and portal vein preparations [8,12,18,23] of normotensive
Open access under the Elsevier OA license.rats; however, to our knowledge, the vascular effects of Ang II
either in veins or venules from hypertensive rats have not been
evaluated. Thus, the aim of the present study was to investigate
the effects of Ang II in the mesenteric venular bed and in the
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ircular muscle of portal veins from spontaneously hypertensive
ats (SHR) by evaluating the participation of AT1R and AT2R on
ng II response. In addition, we analyzed the role of cyclooxyge-
ase (COX) metabolites, nitric oxide (NO), and the kinin B2R in
odulating Ang II-mediated constriction in SHR.
. Methods
.1. Animals
Male Wistar and SHRs weighing 200–300 g were obtained from
he Institute of Biomedical Sciences of the University of São Paulo
ICB-USP). All of the animal experiments were conducted in accor-
ance with the guidelines of the Ethic Committee for Research of
CB-USP and conformed to the Guide for the Care and Use of Lab-
ratory Animals published by the United States National Institutes
f Health (NIH publication No. 85-23, revised 1996). Animals were
ept in a temperature-controlled room on a 12 h light/12 h dark
ycle with 60% humidity, standard rat chow, and water ad libitum.
.2. Mesenteric venular bed preparation
Isolated perfused mesenteric venular bed preparations were
erformed according to the method previously described [37]. After
ats were anesthetized with chloral hydrate (450 mg/kg, s.c.), a can-
ula (PE 50) was inserted retrogradely (1.0 cm) into the portal vein
nd the vascular mesenteric bed was dissected out at its border
ith the intestine. The mesenteric venular bed was  perfused at
 constant rate of 2 mL/min using a peristaltic pump (Miniplus 3,
ilson, France) with Krebs-Henseleit solution, pH 7.4, at 37 ◦C in
he presence of 95% O2 and 5% CO2. To conﬁrm the viability of tis-
ues, preparations were exposed to 90 mmol/L KCl for 5 min. After
0 min  of washing out the KCl with Krebs solution, Ang II (0.1 nmol)
as administered in bolus in a ﬁnal volume of 100 L and vascu-
ar responses were evaluated as changes in the perfusion pressure
mmHg) (PowerLab 4S; ADInstruments, Australia).
.3. Portal vein preparation
Isolated portal vein ring preparations were performed accord-
ng to the method previously described [2].  Rats were anesthetized
ith chloral hydrate (450 mg/kg, s.c.), the portal vein was  excised
nd connective tissue was removed. Rings of portal veins (3–4 mm
ength) were mounted under 0.5 g of passive tension in an organ
ath (15 mL)  containing Krebs-Henseleit solution, pH 7.4, at 37 ◦C
ith 95% O2 and 5% CO2. Preparations were allowed to equilibrate
or 60 min; during this time, the bath solution was  changed every
0 min. To conﬁrm the viability of tissues, the preparations were
xposed to 90 mmol/L KCl for 5 min. After 30 min  of washing out
he KCl with normal Krebs solution, a cumulative-concentration
esponse curve (CCRC) to Ang II (0.1–100 nmol/L) was performed
nd changes in isometric tension (grams) were recorded (Power-
ab 4S, ADInstruments, Australia). CCRC were analyzed by a data
nalyses program (Prism3, GraphPad) to evaluate the EC50 (the con-
entration of Ang II required to produce 50% maximum response)
nd maximum response (Emax). Efﬁcacy and sensitivity of portal
ein rings preparations in response to Ang II was  determined as
max and pEC50 (−log EC50), respectively.
.4. Treatments of Mesenteric venous bed and portal vein ring
reparationsTo investigate the mechanisms involved in Ang II-mediated
ontraction, preparations of mesenteric venous beds and portal
ein rings were incubated with Krebs-Henseleit solution containing
osartan (speciﬁc AT1R antagonist, 0.1 mol/L), PD 123319 (speciﬁc2 (2011) 2116–2121 2117
AT2R antagonist, 0.1 mol/L), HOE 140 (speciﬁc B2R antagonist,
20 nmol/L) [13], indomethacin (COX inhibitor, 10 mol/L), or L-
NAME (inhibitor of NO synthesis, 10 mol/L) 30 min  before Ang
II injection. In addition, a group of SHR were treated with cele-
coxib (speciﬁc COX2 inhibitor, 10 mg/kg) [20] administered by
gavage 3 h before were killed and the mesenteric venular beds and
portal vein rings were prepared. All the concentrations of antag-
onists/inhibitors used in experiments were based in preliminary
studies performed in our laboratory or in the literature, when spec-
iﬁed.
2.5. RNA isolation and cDNA synthesis
Total RNA from the portal veins of SHR and Wistar rats was
extracted using Trizol reagent (Invitrogen, USA) in accordance
with the manufacturer’s protocol. Genomic DNA was digested with
DNase I and ﬁrst-strand cDNA was  synthesized from 2 g of total
RNA in a volume of 20 L, using SuperScript II enzyme (Invitrogen);
RNAse Out (Invitrogen) was  added to protect RNA during this pro-
cess. Samples were incubated at 42 ◦C for 50 min, and the reaction
was stopped by heating the samples at 70 ◦C for 15 min. Samples
were cooled at 4 ◦C for 10 min.
2.6. Real-time PCR
Diluted samples from the reverse transcriptase reaction (1:10)
underwent real-time PCR ampliﬁcation using Platinum SYBR
QPCR Supermix-UDG and speciﬁc primers for AT1R (forward,
CACTTTCCTGGATGTGCTGA; reverse, CCCAGAAAGCCGTAGAACAG;
141 bp) and AT2R (forward, CTGCTGGGATTGCCTTAATGA; reverse,
AGCAGATGTTTTCTGATTCCAAAGT; 94 bp). Gene expression of
GAPDH mRNA was  used for normalization (forward, GGTGCT-
GAGTATGTCGTGGA; reverse, ACTGTGGTCATGAGCCCTTC; 262 bp).
Real-time PCRs were performed, recorded, and analyzed using the
Corbett Research system (Corbett Life Sciences, Australia). The con-
ditions for PCR were as follows: 95 ◦C for 2 min, then 40 cycles of
95 ◦C for 15 s, 60 ◦C for 1 min, and 72 ◦C for 15 s. The speciﬁcity of the
SYBR Green assay was conﬁrmed by melting point analysis. Expres-
sion data were calculated from the cycle threshold (Ct) value using
the Ct method for quantiﬁcation [22]. Results were expressed
as fold increases. All of the reagents utilized in this method were
purchased from Invitrogen (USA).
2.7. Immunohistochemical assay for AT1R and AT2R
Immunohistochemical assay for detection of angiotensin recep-
tors in portal vein was realized according with the method
previously described [4].  The portal vein was ﬁxed with 4%
paraformaldehyde (PFA) solution for 6 h and immersed in sucrose
solution (30%) for 12 h. After that, portal vein was  embedded
in medium for cryosectioning, cut into 8 m thick sections with
a Leica CM 1850 cryostat (Leica Instruments, Germany), and
placed on slides. The vessels were incubated with rabbit anti-
goat AT1R or AT2R antibody (IgG; Santa Cruz Biotechnology, USA)
at 1:25 and 1:10 dilutions, respectively, at 4 ◦C for 18 h. Slides
were washed with phosphate buffered saline (PBS) and incu-
bated with biotin-conjugated secondary antibody (diluted 1:1000;
Vector Laboratory, USA) at room temperature for 2 h. After incu-
bation, slides were washed with PBS and incubated with the ABC
Vectastain kit (Vector Laboratory, USA) at room temperature for
2 h. The signal was revealed by incubating the slides with 3,3-
diaminobenzidine (DAB) (Sigma–Aldrich, USA) and 0.06% H2O2 for
30 and 60 s for the AT1R and AT2R antibodies, respectively. The
semi-quantitative analysis of staining to AT1R and AT2R antibodies
was determined at least in ﬁve portal vein slides from each ani-
mal  and protein expression levels were expressed as arbitrary units
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etermined by optic densitometry with the KS-300 image program
Carl-Zeiss, Germany).
.8. Drugs and reagents
Ang II was from Bachem-CA; HOE 140, PD 123319, L-NAME, and
ndomethacin were from Sigma–Aldrich; losartan was from Merck
harp & Döhme and celecoxib was from Pﬁzer..9. Statistical analysis
Comparisons were made by ANOVA followed by Tukey-Kramer
est or Student’s t-test when appropriate. Values were reported as
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ig. 2. Effect of Ang II on isolated portal vein rings. (A) Representative recording of a CCR
n  isolated portal vein rings from SHR and Wistar rats, expressed as an increase in tensio
ats.  (C) CCRC to Ang II in isolated portal vein rings from SHR in the absence () or presenc
)  or HOE 140 (©). Results represent mean ± SEM, n = 6–8 for each group. *P < 0.05 versu injection of Ang II in the rat isolated mesenteric venular bed. The arrow indicates
ion. Bar graph showing the effect of 0.1 nmol Ang II in isolated mesenteric venular
t mean ± SEM, n = 5–8 for each group. *P < 0.05 versus control.
mean ± standard error of mean (SEM). Statistical signiﬁcance was
set as P < 0.05.
3. Results
3.1. Effect of Ang II on mesenteric venous beds
Ang II injection induced a slight but consistent constriction
in isolated mesenteric venules (Fig. 1A). No signiﬁcant differ-
ences were observed between the responses of Wistar rats
(10.6 ± 1.1 mmHg; n = 6) and SHR (10.6 ± 1.3 mmHg; n = 8).
Basal perfusion pressure in mesenteric venous bed was not
modiﬁed by pre-incubation with different antagonists. In SHR
preparations, the constriction induced by Ang II was  nearly
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Fig. 3. mRNA expression of angiotensin receptors. Bar graph showing mRNA expres-
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bolished (P < 0.05) by perfusion with losartan (0.8 ± 0.2 mmHg;
 = 7), while PD123319 and L-NAME had no effect at all. In contrast,
ng II venoconstriction increased (P < 0.05) after B2R blockade
ith HOE 140 (15.7 ± 1.6 mmHg; n = 8), and also after COX inhi-
ition with indomethacin (16.8 ± 1.5 mmHg, n = 6) or celecoxib
18.8 ± 1.4 mmHg, n = 5). The results are shown in Fig. 1B.
.2. Effect of Ang II on portal vein rings
Starting at 1 nmol/L, Ang II contracted rings of portal vein
n a concentration-dependent manner. The Emax was reached at
0 nmol/L. At concentrations higher than 100 nmol/L, Ang II induces
apid desensitization (tachyphylaxis) in this preparation (Fig. 2A).
Fig. 2B shows the CCRCs to Ang II in both Wistar and SHR
ortal vein preparations. The Emax to Ang II was signiﬁcantly
educed (P < 0.05) in SHR (0.62 ± 0.09; n = 6) compared to Wistar
ats (1.00 ± 0.15; n = 6). No changes were detected in response to
Cl (Wistar: 0.43 ± 0.07 g; n = 7 versus SHR: 0.31 ± 0.06 g; n = 8).
Pre-incubation of portal vein rings from SHR with losar-
an shifted to the right the CCRC to Ang II [Control: pEC50:
.62 ± 0.05 mol/L; n = 6 versus Losartan: 7.95 ± 0.06 mol/L; n = 4
P < 0.05)], whereas PD 123319 treatment had no effect (Fig. 2C).
re-incubation with indomethacin and HOE 140 increased the
max to Ang II [Control: 0.57 ± 0.09 g, n = 8 versus Indomethacin:
.21 ± 0.14 g, n = 7 and HOE 140: 1.01 ± 0.08 g, n = 11 (P < 0.05)], as
emonstrated in Fig. 2D. L-NAME and celecoxib did not alter the
ng II response (data not shown).
.3. Expression of AT1 and AT2 receptors in portal veins
To investigate a possible alteration in angiotensin receptor
xpression between SHR and Wistar rats, we quantiﬁed the levels
f AT1R and AT2R mRNA in samples from portal veins. The results
re shown in Fig. 3.
While no differences were detected in AT1R expression, AT2R
RNA levels in the portal vein samples were signiﬁcantly reduced
ig. 4. Representative image of immunohistochemical staining of AT1R and AT2R 400× 
taining in portal vein from Wistar rat (C) and SHR (D). [I] indicates intimal layer; [A] indsion of AT1R and AT2R in portal veins from Wistar rats and SHR. Results from
real-time PCR represent mean ± SEM, and were normalized to GAPDH mRNA expres-
sion; n = 5–7. *P < 0.05 versus Wistar rats.
in SHR [0.34 ± 0.13 arbitrary units (a.u.); n = 7; P < 0.05] compared
to Wistar rats (1.05 ± 0.19 a.u.; n = 4) (Fig. 3).
Immunohistochemical assays revealed similar results. Fig. 4
contains representative images of immunohistochemical staining
for AT1R and AT2R in SHR and Wistar rats. AT1R and AT2R were
present in the endothelium, vascular smooth muscle cells, and
adventitial layer. There was no difference in AT1R expression in
SHR and Wistar rats, while AT2R expression was reduced in the
portal veins of SHR (6.85 ± 0.50 a.u.; n = 5; P < 0.05) compared to
Wistar rats (9.08 ± 0.25 a.u.; n = 5) (Fig. 5).
4. Discussion
Ang II evoked a consistent constriction in mesenteric venules
and portal vein from SHR. In both vascular preparations, losar-
tan reduced or nearly abolished the Ang II-mediated constriction,
while PD123319 did not modify this response. Ang II-induced
venoconstriction was markedly increased by indomethacin, while
celecoxib was  effective only in mesenteric venules. Whereas vascu-
lar responses to Ang II were augmented by HOE-140, L-NAME had
no effect. By analyzing our results, we  found that Ang II-induced
magniﬁcation. AT1R staining in portal vein from Wistar rat (A) and SHR (B). AT2R
icates adventitial layer and [arrows] indicates antibody staining.
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onstriction in mesenteric venules and portal vein from SHR is
ependent of AT1R activation and counterbalanced by COX metabo-
ites and kinin B2R.
Several aspects of our results may  point to important differences
etween the venous system of normotensive and hypertensive
ats. For instance, Ang II-induced constriction was signiﬁcantly
ttenuated in portal vein rings from SHR. Besides, Ang II-induced
enoconstriction was mediated by both AT1R and AT2R in nor-
otensive rats [8]. Considering these ﬁndings, we hypothesized
hat differences between strains could be related to changes in
ngiotensin receptors expression. In fact, when AT1R and AT2R
ere evaluated, the AT2R expression was signiﬁcantly reduced in
ortal vein from SHR. Although several studies have investigated
he inﬂuence of AT2R in the vascular system, the functional role
f this subtype is not completely elucidated. Authors have demon-
trated that AT2R activation can induce both vasodilation [39] and
asoconstriction [34,40]. In this regard, a consistent vasoconstric-
or effect of Ang II mediated by AT2R in mesenteric arterioles of
HR has been demonstrated [34,40]. Moreover, AT2R also partici-
ates of contractile effect of Ang II in portal vein preparations from
ormotensive rats [8,23].  Probably, reduction of AT2R levels in por-
al vein from SHR can be responsible for the decreased response
bserved by us. This result can indicate that AT2R plays a distinct
ole in the vasculature of normotensive and hypertensive rats.
The basic hemodynamic disturbance in established hyper-
ension is an elevation of total peripheral resistance, which is
etermined mainly by resistance vessels from arterial system. In
act, it is well established that hypertensive patients have similar
alues of cardiac output in comparison with normotensive controls
nd the elevated blood pressure is maintained by increase in total
eripheral resistance [16,26]. Similarly, it was demonstrated that
ardiac output is not altered in SHR, a generally accepted model
or human essential hypertension [31,36]. From this point of view,
educed Ang II response observed in venous from SHR would not be
nﬂuencing cardiac output control. However, considering that Ang
I-induced constriction is augmented in arteries from hyperten-
ive animals [6,11,13], reduction of Ang II responses in the venous
ystem could be related to a compensatory mechanism, avoiding
xaggerated increase in venous return and alterations in cardiac
utput.
The kalikrein–kinin system plays an important role in the main-
enance of cardiovascular homeostasis. In this regard, the kinin
2R null mice present high sensitivity to hypertensive stimuli [1,5],
mpairment of endothelium-dependent vasodilation and decrease
n NO bioavailability [15]. Moreover, studies have indicated the
xistence of functional interactions between angiotensin and kinin
eceptors in vascular cells. In this respect, Seyed et al. [29] demon-
trated that Ang II-mediated vasodilation in coronary vessels from
ogs is dependent of B2R. This interaction was also observed
n arteries from normotensive [9,19] and hypertensive rats [21].
[2 (2011) 2116–2121
The present data suggest that Ang II-induced constriction is also
counterbalanced by B2R activation in venules and veins from hyper-
tensive rats. Therefore, the ﬁnal effects resulted from Ang II, at least
on these vascular beds, should be considered as a combination of
AT1R signaling in the presence of a modulating action elicited by
B2R. Further studies will reveal the physiological and pathophysi-
ological consequences of this phenomenon.
Whereas COX metabolites appear to counterbalance the Ang
II-induced venoconstriction in SHR, our data do not suggest the par-
ticipation of NO in this effect. In normotensive rats, Fernandes et al.
[8] demonstrated that NO counteracts the Ang II-induced venocon-
striction, while COX metabolites were not involved in this response.
Similar results were observed in mesenteric arterioles from nor-
motensive rats [19]. It has been suggested that alteration in NO
metabolism is implicated in endothelial dysfunction, a common
denominator in essential hypertension [7].  In fact, several vascular
beds of SHR present impaired endothelium-dependent vasodila-
tion [14,17,33].  In this regard, increased production of superoxide
anion in vessels of SHR has been associated to NO inactivation and
elevation of the blood pressure [28]. Our data suggest that produc-
tion of vasodilatory eicosanoids in venous bed from SHR represent
an alternative pathway to attenuate the Ang II-induced constric-
tion at low levels of NO. Moreover, COX metabolites probably are
involved in impairment of Ang II-induced constriction in portal vein
from SHR.
Concluding, in SHR, the attenuation of Ang II-induced veno-
constriction by COX metabolites and B2R may be involved in the
local response to conserve the normal cardiac output in estab-
lished hypertension. Taken together, our data indicate that different
mechanisms are involved in the regulation of venous tonus of nor-
motensive and hypertensive rats. These differences probably reﬂect
distinct factors that inﬂuence arterial and venous bed in hyperten-
sion.
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